Drug profile · INN
phenprocoumon
LIQUAMAR
phenprocoumon (LIQUAMAR) is a vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — phenprocoumon
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
phenprocoumon (LIQUAMAR) is a vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
Primary target: Vitamin K epoxide reductase complex subunit 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is phenprocoumon?
phenprocoumon (LIQUAMAR) is a vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for phenprocoumon?
LIQUAMAR is a marketed brand name for phenprocoumon. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of phenprocoumon?
phenprocoumon has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.